Thematic review series: The Pathogenesis of Atherosclerosis Published, JLR Papers in Press, April 1, 2004. DOI 10.1194/jlr.R400001-JLR200 The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL

For more than two decades, there has been continuing evidence of lipid oxidation playing a central role in atherogenesis. The oxidation hypothesis of atherogenesis has evolved to focus on specific proinflammatory oxidized phospholipids that result from the oxidation of LDL phospholipids containing arachidonic acid and that are recognized by the innate immune system in animals and humans. These oxidized phospholipids are largely generated by potent oxidants produced by the lipoxygenase and myeloperoxidase pathways. The failure of antioxidant vitamins to influence clinical outcomes may have many explanations, including the inability of vitamin E to prevent the formation of these oxidized phospholipids and other lipid oxidation products of the myeloperoxidase pathway. Preliminary data suggest that the oxidation hypothesis of atherogenesis and the reverse cholesterol transport hypothesis of atherogenesis may have a common biological basis. The levels of specific oxidized lipids in plasma and lipoproteins, the levels of antibodies to these lipids, and the inflammatory/anti-inflammatory properties of HDL may be useful markers of susceptibility to atherogenesis. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides may both promote a reduction in oxidized lipids and enhance reverse cholesterol transport and therefore may have therapeutic potential.

[1]  R. Natarajan,et al.  12/15-Lipoxygenase Activity Mediates Inflammatory Monocyte/Endothelial Interactions and Atherosclerosis in Vivo* , 2004, Journal of Biological Chemistry.

[2]  J. Sundvall,et al.  Periodontitis decreases the antiatherogenic potency of high density lipoprotein Published, JLR Papers in Press, September 16, 2003. DOI 10.1194/jlr.M300250-JLR200 , 2004, Journal of Lipid Research.

[3]  M. Cathcart,et al.  Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[4]  Stanley L. Hazen,et al.  Identification of &agr;-Chloro Fatty Aldehydes and Unsaturated Lysophosphatidylcholine Molecular Species in Human Atherosclerotic Lesions , 2003 .

[5]  Shirin Rahmani,et al.  Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment , 2003, Circulation.

[6]  S. Hazen,et al.  Isolevuglandins, a novel class of isoprostenoid derivatives, function as integrated sensors of oxidant stress and are generated by myeloperoxidase in vivo , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  D. Rader.  High-density lipoproteins as an emerging therapeutic target for atherosclerosis. , 2003, JAMA.

[8]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[9]  E. Topol,et al.  Prognostic value of myeloperoxidase in patients with chest pain. , 2003, The New England journal of medicine.

[10]  J. Witztum,et al.  Oxidized low density lipoprotein and innate immune receptors , 2003, Current opinion in lipidology.

[11]  A. Tall,et al.  Phosphorylation of a Pest Sequence in ABCA1 Promotes Calpain Degradation and Is Reversed by ApoA-I* , 2003, Journal of Biological Chemistry.

[12]  J. Heinecke,et al.  Oxidized HDL: the paradox-idation of lipoproteins. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[13]  G. Francis,et al.  Administration of Tyrosyl Radical–Oxidized HDL Inhibits the Development of Atherosclerosis in Apolipoprotein E–Deficient Mice , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[14]  N. Sibinga,et al.  Absence of heme oxygenase‐1 exacerbates atherosclerotic lesion formation and vascular remodeling , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  M. Reilly,et al.  Overexpression of Apolipoprotein A-I Promotes Reverse Transport of Cholesterol From Macrophages to Feces In Vivo , 2003, Circulation.

[16]  S. Hazen,et al.  Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment , 2003, Current opinion in lipidology.

[17]  U. P. S. T. Force.  Routine Vitamin Supplementation To Prevent Cancer and Cardiovascular Disease: Recommendations and Rationale , 2003, Annals of Internal Medicine.

[18]  C. Morris,et al.  Routine Vitamin Supplementation To Prevent Cardiovascular Disease: A Summary of the Evidence for the U.S. Preventive Services Task Force , 2003, Annals of Internal Medicine.

[19]  M. Hayden,et al.  Restoration of Endothelial Function by Increasing High‐Density Lipoprotein in Subjects With Isolated Low High‐Density Lipoprotein , 2003, Circulation.

[20]  E. Topol,et al.  Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials , 2003, The Lancet.

[21]  J. Witztum,et al.  Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL , 2003, Nature Medicine.

[22]  K. Pritchard,et al.  L-4F, an Apolipoprotein A-1 Mimetic, Dramatically Improves Vasodilation in Hypercholesterolemia and Sickle Cell Disease , 2003, Circulation.

[23]  S. Hazen,et al.  Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. , 2003, JAMA.

[24]  K. Pritchard,et al.  L-4F, an Apolipoprotein A-1 Mimetic, Restores Nitric Oxide and Superoxide Anion Balance in Low-Density Lipoprotein-Treated Endothelial Cells , 2003, Circulation.

[25]  J. Heinecke.  Clinical trials of vitamin E in coronary artery disease: Is it time to reconsider the low-density lipoprotein oxidation hypothesis? , 2003, Current atherosclerosis reports.

[26]  J. Heinecke.  Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. , 2003, The American journal of cardiology.

[27]  Marie-Luise Brennan,et al.  Myeloperoxidase Functions as a Major Enzymatic Catalyst for Initiation of Lipid Peroxidation at Sites of Inflammation* , 2002, The Journal of Biological Chemistry.

[28]  J. Witztum,et al.  Innate and acquired immunity in atherogenesis , 2002, Nature Medicine.

[29]  S. Reddy,et al.  ATP-Binding Cassette Transporter 1 Participates in LDL Oxidation by Artery Wall Cells , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[30]  H. Hashimoto,et al.  Heme Oxygenase-1 Gene Promoter Polymorphism Is Associated With Coronary Artery Disease in Japanese Patients With Coronary Risk Factors , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[31]  D. Rader,et al.  Selective Interleukin-12 Synthesis Defect in 12/15-Lipoxygenase-deficient Macrophages Associated with Reduced Atherosclerosis in a Mouse Model of Familial Hypercholesterolemia* , 2002, The Journal of Biological Chemistry.

[32]  M. Fishbein,et al.  Influenza Infection Promotes Macrophage Traffic Into Arteries of Mice That Is Prevented by D-4F, an Apolipoprotein A-I Mimetic Peptide , 2002, Circulation.

[33]  A. Tward,et al.  Decreased Atherosclerotic Lesion Formation in Human Serum Paraoxonase Transgenic Mice , 2002, Circulation.

[34]  Doris A Taylor,et al.  Cardiac chimerism as a mechanism for self-repair: does it happen and if so to what degree? , 2002, Circulation.

[35]  R. Hotchkiss,et al.  Myeloperoxidase produces nitrating oxidants in vivo. , 2002, The Journal of clinical investigation.

[36]  D. Steinberg,et al.  Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis?: Do the Antioxidant Trials Conducted to Date Refute the Hypothesis? , 2002, Circulation.

[37]  G. Zimmerman,et al.  Activation of vascular cells by PAF-like lipids in oxidized LDL. , 2002, Vascular pharmacology.

[38]  J. Berliner,et al.  Hydroxy alkenal phospholipids regulate inflammatory functions of endothelial cells. , 2002, Vascular pharmacology.

[39]  J. Witztum,et al.  Epoxyisoprostane and Epoxycyclopentenone Phospholipids Regulate Monocyte Chemotactic Protein-1 and Interleukin-8 Synthesis , 2002, The Journal of Biological Chemistry.

[40]  R. Krauss,et al.  Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. , 2002, Journal of lipid research.

[41]  R. Lallone,et al.  Oral Administration of an Apo A-I Mimetic Peptide Synthesized From D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol , 2002, Circulation.

[42]  B. Binder,et al.  Oxidized Membrane Vesicles and Blebs From Apoptotic Cells Contain Biologically Active Oxidized Phospholipids That Induce Monocyte‐Endothelial Interactions , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[43]  D. Shih,et al.  CHD and Atherosclerosis: Human Epidemiological Studies and Transgenic Mouse Models , 2002 .

[44]  P. Ridker.  On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. , 2002, Circulation.

[45]  Lei Zhao,et al.  12/15-Lipoxygenase Gene Disruption Attenuates Atherogenesis in LDL Receptor–Deficient Mice , 2001, Circulation.

[46]  S. Parthasarathy,et al.  Did the antioxidant trials fail to validate the oxidation hypothesis? , 2001, Current atherosclerosis reports.

[47]  S. Reddy,et al.  A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. , 2001, Journal of lipid research.

[48]  S. Kaul,et al.  High-Dose Recombinant Apolipoprotein A-IMilano Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice: Potential Implications for Acute Plaque Stabilization , 2001, Circulation.

[49]  K. Feingold,et al.  Cholesterol efflux by acute-phase high density lipoprotein: role of lecithin: cholesterol acyltransferase. , 2001, Journal of lipid research.

[50]  D. Nayak,et al.  High-Density Lipoprotein Loses Its Anti-Inflammatory Properties During Acute Influenza A Infection , 2001, Circulation.

[51]  D. Rader,et al.  Absence of 12/15-Lipoxygenase Expression Decreases Lipid Peroxidation and Atherogenesis in Apolipoprotein E—Deficient Mice , 2001, Circulation.

[52]  D. Shih,et al.  HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[53]  G. Chisolm,et al.  Oxidized LDL-induced injury and apoptosis in atherosclerosis. Potential roles for oxysterols. , 2001, Trends in cardiovascular medicine.

[54]  D. Sorescu,et al.  NAD(P)H oxidases and their relevance to atherosclerosis. , 2001, Trends in cardiovascular medicine.

[55]  G. Zimmerman,et al.  Oxidized LDL contains inflammatory PAF-like phospholipids. , 2001, Trends in cardiovascular medicine.

[56]  G. Anantharamaiah,et al.  A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. , 2001, Journal of lipid research.

[57]  A. Lusis,et al.  Heme Oxygenase-1 Inhibits Atherosclerotic Lesion Formation in LDL-Receptor Knockout Mice , 2001, Circulation research.

[58]  G. FitzGerald,et al.  Effects of vitamin E on lipid peroxidation in healthy persons. , 2001, JAMA.

[59]  J. Crowley,et al.  Increased atherosclerosis in myeloperoxidase-deficient mice. , 2001, The Journal of clinical investigation.

[60]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[61]  Hans Lee,et al.  Determinants of Bioactivity of Oxidized Phospholipids: Specific Oxidized Fatty Acyl Groups at the sn-2 Position , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[62]  S. Reddy,et al.  Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. , 2000, Journal of lipid research.

[63]  J. George,et al.  Overexpression of 15-Lipoxygenase in Vascular Endothelium Accelerates Early Atherosclerosis in LDL Receptor–Deficient Mice , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[64]  A. Carr,et al.  Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[65]  G. Silverman,et al.  Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. , 2000, The Journal of clinical investigation.

[66]  D. Shih,et al.  Combined Serum Paraoxonase Knockout/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and Atherosclerosis* , 2000, The Journal of Biological Chemistry.

[67]  G. Fonarow,et al.  formation of , 2022 .

[68]  J. Lee,et al.  Toward the bilayer proteome, electrospray ionization-mass spectrometry of large, intact transmembrane proteins. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[69]  J. Berliner,et al.  Structural Identification of a Novel Pro-inflammatory Epoxyisoprostane Phospholipid in Mildly Oxidized Low Density Lipoprotein* , 1999, The Journal of Biological Chemistry.

[70]  J. Heinecke.  Is lipid peroxidation relevant to atherogenesis? , 1999, The Journal of clinical investigation.

[71]  R. Stocker,et al.  Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits. , 1999, The Journal of clinical investigation.

[72]  D. Steinberg.  At last, direct evidence that lipoxygenases play a role in atherogenesis. , 1999, The Journal of clinical investigation.

[73]  D. Rader,et al.  Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. , 1999, The Journal of clinical investigation.

[74]  E. Dennis,et al.  Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: implications with respect to macrophage recognition of apoptotic cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[75]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[76]  E. Dennis,et al.  Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. , 1999, The Journal of clinical investigation.

[77]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[78]  G. Francis,et al.  Enhanced Cholesterol Efflux by Tyrosyl Radical-oxidized High Density Lipoprotein Is Mediated by Apolipoprotein AI-AII Heterodimers* , 1998, The Journal of Biological Chemistry.

[79]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[80]  A. Daugherty,et al.  A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. , 1998, Atherosclerosis.

[81]  J L Witztum,et al.  Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. , 1997, The Journal of clinical investigation.

[82]  T. Drake,et al.  Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. , 1997, Circulation research.

[83]  Wei Sha,et al.  Structural Identification by Mass Spectrometry of Oxidized Phospholipids in Minimally Oxidized Low Density Lipoprotein That Induce Monocyte/Endothelial Interactions and Evidence for Their Presence in Vivo * , 1997, The Journal of Biological Chemistry.

[84]  G. Fonarow,et al.  Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. , 1997, The Journal of clinical investigation.

[85]  F. Ursini,et al.  LDL- is a lipid hydroperoxide-enriched circulating lipoprotein. , 1997, Journal of lipid research.

[86]  R. D. Dyer,et al.  Attenuation of diet‐induced atherosclerosis in rabbits with a highly selective 15‐lipoxygenase inhibitor lacking significant antioxidant properties , 1997, British journal of pharmacology.

[87]  J. Cornhill,et al.  Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. , 1996, The Journal of clinical investigation.

[88]  R. Stocker,et al.  Rapid reduction and removal of HDL- but not LDL-associated cholesteryl ester hydroperoxides by rat liver perfused in situ. , 1996, The Biochemical journal.

[89]  D. Stafforini,et al.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. , 1995, The Journal of clinical investigation.

[90]  J. Berliner,et al.  Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[91]  M. Kendall,et al.  The oxidation hypothesis of atherosclerosis , 1994, The Lancet.

[92]  A. Lusis,et al.  Role of the GRO family of chemokines in monocyte adhesion to MM-LDL-stimulated endothelium. , 1994, The Journal of clinical investigation.

[93]  J. Breslow,et al.  Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[94]  R. Stocker,et al.  High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[95]  B. Auerbach,et al.  A spectrophotometric microtiter-based assay for the detection of hydroperoxy derivatives of linoleic acid. , 1992, Analytical biochemistry.

[96]  A. Fogelman,et al.  Monocytes may amplify their recruitment into inflammatory lesions by inducing monocyte chemotactic protein. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[97]  A. J. Valente,et al.  Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. , 1991, The Journal of clinical investigation.

[98]  D. Steinberg.  Antioxidants and atherosclerosis. A current assessment. , 1991, Circulation.

[99]  A. Lusis,et al.  Minimally modified low density lipoprotein is biologically active in vivo in mice. , 1991, The Journal of clinical investigation.

[100]  A. Lusis,et al.  Interaction of monocytes with cocultures of human aortic wall cells involves interleukins 1 and 6 with marked increases in connexin43 message. , 1991, The Journal of clinical investigation.

[101]  P. Hjemdahl,et al.  Stress‐induced changes in blood pressure and left ventricular function in mild hypertension , 1991, Clinical cardiology.

[102]  G. Chisolm.  Antioxidants and atherosclerosis: A current assessment , 1991, Clinical cardiology.

[103]  D. Steinberg,et al.  Role of oxidised low density lipoprotein in atherogenesis. , 1993, British heart journal.

[104]  A. J. Valente,et al.  Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[105]  V. Fuster,et al.  Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. , 1990, The Journal of clinical investigation.

[106]  M. Territo,et al.  Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. , 1990, The Journal of clinical investigation.

[107]  A. Lusis,et al.  Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins , 1990, Nature.

[108]  J L Witztum,et al.  Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. , 1989, The Journal of clinical investigation.

[109]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[110]  M. Haberland,et al.  Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. , 1988, Science.

[111]  P. Wilson,et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.

[112]  A. Chait,et al.  Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. , 1984, The Journal of clinical investigation.

[113]  D. Morel,et al.  Endothelial and Smooth Muscle Cells Alter Low Density Lipoprotein In Vitro by Free Radical Oxidation , 1984, Arteriosclerosis.

[114]  J L Witztum,et al.  Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[115]  D. Steinberg,et al.  Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[116]  P. Edwards,et al.  Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[117]  G. Chisolm,et al.  LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. , 1979, Atherosclerosis.

[118]  M. Brown,et al.  Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[119]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[120]  Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway , 2022 .